CADD Methods for Developing Novel Compounds Synthesized to Inhibit Tyrosine Kinase Receptors

Area of Science:

• Biochemistry
• Pharmacology
• Computational Biology

Background:

• Growth factors and receptor tyrosine kinases are crucial for cell functions and implicated in cancer development, especially angiogenesis.
• Current FDA-approved tyrosine kinase inhibitors targeting angiogenesis show promise but limitations necessitate new drug development.
• In silico studies offer significant cost and time advantages for drug design and discovery.

Purpose of the Study:

• To review recent (2022-2024) in silico research on novel drug candidates for cancer treatment.
• To focus on drugs targeting tyrosine kinase receptors involved in angiogenesis.
• To identify emerging computational strategies in anti-angiogenic cancer therapy.

Main Methods:

• Systematic literature review of in silico studies published between 2022 and 2024.
• Analysis of computational approaches for designing tyrosine kinase inhibitors.
• Focus on studies targeting angiogenesis pathways in cancer.

Main Results:

• Identification of several promising new drug candidates through in silico drug design.
• Validation of computational methods for predicting efficacy against tyrosine kinase targets.
• Emerging trends in targeting angiogenesis via novel molecular scaffolds.

Conclusions:

• In silico approaches are vital for accelerating the discovery of novel anti-cancer drugs.
• Targeting tyrosine kinases involved in angiogenesis remains a key strategy in cancer therapy.
• Continued in silico research is essential for developing next-generation cancer treatments.